BetaGlue Therapeutics

medical devices

About

BetaGlue Therapeutics is an Italian clinical-stage life sciences company focused on innovative cancer treatment through its internal radiotherapy platform, YntraDose®. This technology allows for the precise and personalized delivery of radiotherapy directly into solid tumors, enhancing treatment efficacy while minimizing side effects. The company aims to provide cost-effective and easy-to-use radiotherapy solutions for patients with solid tumors. YntraDose® is designed for targeted treatment, particularly for unresectable tumors and post-surgical care, making it a valuable option for interventional radiologists and healthcare providers. BetaGlue Therapeutics operates in the global oncology market, generating revenue through the sale of its proprietary medical devices and pursuing partnerships to expand its reach. With significant funding support, the company is well-positioned to advance its mission of improving cancer care worldwide.

Technologies

OutlookMicrosoft Office 365WordPress.orgApacheGravity FormsVimeoGoogle Font APIMobile FriendlyAI

Keywords

radiotherapynuclear medicineoncologymedical devicesmedical equipment manufacturingorgan movement compensationbiocompatible bioglueorgan-specific treatmenttargeted tumor ablationimaging guidancetreatment safetyoncology innovationinternal radiotherapyd2cmedical deviceefficacy outcomeshealthcare technologytreatment efficacytreatment accessibilityinterventional oncologyb2bhydrogel matrix loaded with y-90healthcaretargeted cancer therapyorgan preservationsolid tumor treatmentpercutaneous radiotherapysingle session radiotherapyintratumoral injectionlocal dose escalation

Location

4 Piazzetta Umberto Giordano, Milan, Lombardy, Italy, 20122

Related Companies

Companies in the same industry